6-Maleimidocapronic acid
CAS No. 55750-53-3
6-Maleimidocapronic acid( —— )
Catalog No. M24546 CAS No. 55750-53-3
6-Maleimidocapronic acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 49 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name6-Maleimidocapronic acid
-
NoteResearch use only, not for human use.
-
Brief Description6-Maleimidocapronic acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.
-
Description6-Maleimidocapronic acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.
-
In VitroPROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
-
In Vivo——
-
Synonyms——
-
PathwayPROTACs
-
TargetPROTAC
-
RecptorAlkyl-Chain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number55750-53-3
-
Formula Weight211.21
-
Molecular FormulaC10H13NO4
-
Purity>98% (HPLC)
-
SolubilityDMSO: 190 mg/mL (899.58 mM; Need ultrasonic)
-
SMILESO=C(N1CCCCCC(O)=O)C=CC1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562
molnova catalog
related products
-
BM-PEG3
BM-PEG3 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
dTRIM24
dTRIM24 is a potent TRIM24 bromodomain inhibitor with IC50 of 217.8 nM (TRIM24 ligand displacement).
-
BRD4 degrader AT1
BRD4 degrader AT1 is a highly selective BED4 degrader (PROTAC), exhibits highly selective depletion of BRD4 in cells with negligible activity against BRD2 and BRD3.
Cart
sales@molnova.com